Common Contracts
1 similar null contracts
ContractOctober 19th, 2021
Clinical Trial Agreement Protocol # MOR208C310Trial Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high- risk patients with newly-diagnosed diffuse large B- cell lymphoma (DLBCL) This Clinical Trial Agreement (“Agreement”) is entered into by and among the following parties: MorphoSys AG, a German company with a principal place of business at Semmelweisstrasse 7, 82152 Planegg, Germany (“Sponsor”) and East Slovakia Cancer Institute, with a place of business at Rastislavova 43, 041 91 Kosice, Slovak republic, ID: 36603350, VAT ID: SK2022124159, companyregistered in the Commercial Register of the District Court of Košice I., file no. 1371 / V, section: Sa, represented by Tomas Sieber, M.D., MPH, Eva Mila, Eng, Vice-Chairperson, Igor Jenčo, M.D. – member: (hereinafter the “Institution”); and shall become eff
